235 Users Online
Actinic Prurigo Treatment Market Segmented By Medication such as Emollients, Topical steroids, Antimalarial in Oils, Lotions, Creams, Ointments, Gel or solution form type
Actinic prurigo, also known as sun allergy or Hutchinson prurigo, is a condition of the skin reaction triggered by sunlight. These changes cause the immune system to incorrectly identify the proteins in the skin cells as damaging invaders. The symptoms included are severe itching and painful inflammation of sun-exposed skin, for some people the reactions are severe which results to the formation of small blisters or hives that often spreads unto the skin’s clothed areas.
According to the British Association of Dermatologists, women are more susceptible to actinic prurigo than men, by the ratio of 2:1. Besides, actinic prurigo affects all skin types but more commonly the Latin American and American Indians of darker skin tone.
Therefore, it’s common in Central and South America and Mexico, where it often affects people who are residing at high altitude. It is rarely in Europe and Asia. The global actinic prurigo treatment market is expected to grow further due to its increasing prevalence, rising awareness and availability of medical advanced treatments.
Coronavirus has negatively impacted several economies and industries including the actinic prurigo, with the massive imposition of lockdown, temporary shutdown of industries and offices. The R&D funds and research focus has been diverted to COVID-19 vaccine development, which has staggered the growth of other medical research areas such as actinic prurigo. However, with the restoration of normalcy in the market and medical research areas, the actinic prurigo treatment market is expected to leverage in future.
Growing cases of allergic disorders is the primary factory driving the growth of actinic prurigo market. Moreover, inclination toward advance technologies also boosting the revenue growth for the market. For instance, thalidomide has been described as the hallmark therapy for severe refractory cases of actinic prurigo.
Treatment with thalidomide has a major limiting side effect profile, which includes peripheral neuropathy and teratogenicity, which will further contribute to drive the market for actinic prurigo in the near future. Although, with the advancing medical treatments of actinic prurigo and its escalating research and rising awareness, the global actinic prurigo treatment market is expected to elevate further.
However, allergy treatment is majorly hamper by side effects of anti-allergy drugs coupled with high treatment cost is the major challenge that will limit the market growth.
|Based on Medication||
|Based on Form type||
|Based on Distribution Channel||
The global actinic prurigo treatment market is expected to show a robust growth owing to increasing prevalence of actinic prurigo, rising awareness of the disease, availability of treatments such as sunscreen ointments and other OTC. By medication, emollients are anticipated to rule the segment due to their skin relieving properties and high acceptance by user.
By form type, the market is divided into oils lotion, cream, ointments and gel or solution. By distribution channel, the hospital retailers are expected to rule the segment with their advanced diagnostics and prescribed medicated products for actinic prurigo.
North America is expected to hold the prominent share in the market for actinic prurigo due to rise in prevalence and awareness of actinic prurigo, advanced healthcare infrastructure and R&D expenditure. Europe is expected to hold the next major revenue share for actinic prurigo treatment market due to its advanced healthcare and diagnostic technology, and availability of sun-screen ointments and other treatments.
Asia Pacific is expected to grow further for actinic prurigo treatment market owing to the huge population base, increasing awareness of actinic prurigo and progressing healthcare infrastructure. Latin America actinic prurigo treatment market is expected to grow at faster rate with the rising awareness and massive prevalence of the actinic prurigo. Middle East and Africa is expected to be the least lucrative region due to dire healthcare infrastructure and lack of knowledge of actinic prurigo.
The key player of the global actinic prurigo treatment market includes Pfizer Inc., Novartis AG, Sanofi, Johnson & Johnson, Merck KGaA, Sun Pharmaceutical Industries Ltd., GlaxoSmithKline plc., Cipla Inc. and others.